Clinical Trials Logo

Chikungunya Fever clinical trials

View clinical trials related to Chikungunya Fever.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04483466 Enrolling by invitation - Clinical trials for Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease Severity

Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)

Start date: July 18, 2023
Phase: Phase 3
Study type: Interventional

MARCH is the first randomized, double-blind, placebo-controlled evaluation of the efficacy and pathologic mechanism determined by synovial biopsy of 6 months of methotrexate (n=100) versus placebo (n=50) therapy for chronic chikungunya (CHIKV) arthritis in Colombia with the option for open-label use of the medication for up to one year for all participants. Our central hypothesis is that methotrexate will significantly decrease chronic CHIKV arthritis disease severity compared to placebo via suppression of leukocyte accumulation in synovial tissue and decreased expression of inflammatory cytokines from synovial macrophages and fibroblast-like synoviocytes (FLS).